Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia
Newron Pharmaceuticals secures up to EUR 38 million to advance evenamide Phase III trials. Find out what this means for treatment-resistant schizophrenia.